AKR1C3 Antibody - #DF6613
製品説明
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
引用形式: Affinity Biosciences Cat# DF6613, RRID:AB_2838575.
折りたたみ／展開
17 beta HSD 5; 17 beta hydroxysteroid dehydrogenase type 5; 17-beta-HSD 5; 17-beta-hydroxysteroid dehydrogenase type 5; 2-dihydrobenzene-1; 2-diol dehydrogenase; 20-alpha-hydroxysteroid dehydrogenase; 3 alpha hydroxysteroid dehydrogenase type II; 3-alpha-HSD type 2; 3-alpha-HSD type II; 3-alpha-HSD type II, brain; 3-alpha-hydroxysteroid dehydrogenase type 2; AK1C3_HUMAN; AKR1 C3; Akr1c18; AKR1C3; Aldo keto reductase family 1 member C3; Aldo-keto reductase family 1 member C3; brain; Chlordecone reductase; Chlordecone reductase homolog HAKRb; DD-3; DD3; DDH1; DDX; Dihydrodiol dehydrogenase 3; Dihydrodiol dehydrogenase type I; Dihydrodiol dehydrogenase X; HA1753; HAKRB; HAKRe; hluPGFS; HSD17B5; Indanol dehydrogenase; KIAA0119; PGFS; Prostaglandin F synthase; Testosterone 17-beta-dehydrogenase 5; Trans-1; Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase; Type IIb 3 alpha hydroxysteroid dehydrogenase;
免疫原
Expressed in many tissues including adrenal gland, brain, kidney, liver, lung, mammary gland, placenta, small intestine, colon, spleen, prostate and testis. The dominant HSD in prostate and mammary gland. In the prostate, higher levels in epithelial cells than in stromal cells. In the brain, expressed in medulla, spinal cord, frontotemporal lobes, thalamus, subthalamic nuclei and amygdala. Weaker expression in the hippocampus, substantia nigra and caudate.
- P42330 AK1C3_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MDSKHQCVKLNDGHFMPVLGFGTYAPPEVPRSKALEVTKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWSTFHRPELVRPALENSLKKAQLDYVDLYLIHSPMSLKPGEELSPTDENGKVIFDIVDLCTTWEAMEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNRSKLLDFCKSKDIVLVAYSALGSQRDKRWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTAEDMKAIDGLDRNLHYFNSDSFASHPNYPYSDEY
PTMs - P42330 基板として
| Site | PTM Type | Enzyme | Source |
|---|---|---|---|
| K9 | Sumoylation | Uniprot | |
| Y24 | Phosphorylation | Uniprot | |
| K33 | Ubiquitination | Uniprot | |
| K39 | Ubiquitination | Uniprot | |
| S51 | Phosphorylation | Uniprot | |
| Y55 | Phosphorylation | Uniprot | |
| S67 | Phosphorylation | Uniprot | |
| K68 | Ubiquitination | Uniprot | |
| S73 | Phosphorylation | Uniprot | |
| K75 | Acetylation | Uniprot | |
| K75 | Sumoylation | Uniprot | |
| K75 | Ubiquitination | Uniprot | |
| Y81 | Phosphorylation | Uniprot | |
| T82 | Phosphorylation | Uniprot | |
| S83 | Phosphorylation | Uniprot | |
| K105 | Acetylation | Uniprot | |
| Y110 | Phosphorylation | Uniprot | |
| S118 | Phosphorylation | Uniprot | |
| S129 | Phosphorylation | Uniprot | |
| T147 | Phosphorylation | Uniprot | |
| K161 | Ubiquitination | Uniprot | |
| S162 | Phosphorylation | Uniprot | |
| S166 | Phosphorylation | Uniprot | |
| K179 | Ubiquitination | Uniprot | |
| K183 | Ubiquitination | Uniprot | |
| K185 | Ubiquitination | Uniprot | |
| Y196 | Phosphorylation | Uniprot | |
| K201 | Ubiquitination | Uniprot | |
| K207 | Ubiquitination | Uniprot | |
| S208 | Phosphorylation | Uniprot | |
| K209 | Acetylation | Uniprot | |
| K209 | Ubiquitination | Uniprot | |
| S232 | Phosphorylation | Uniprot | |
| K246 | Acetylation | Uniprot | |
| K246 | Ubiquitination | Uniprot | |
| K247 | Acetylation | Uniprot | |
| K247 | Ubiquitination | Uniprot | |
| K270 | Acetylation | Uniprot | |
| K270 | Ubiquitination | Uniprot | |
| Y272 | Phosphorylation | Uniprot | |
| Y305 | Phosphorylation | Uniprot | |
| Y319 | Phosphorylation | Uniprot | |
| S320 | Phosphorylation | Uniprot | |
| Y323 | Phosphorylation | Uniprot |
研究背景
Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone.
Cytoplasm.
Expressed in many tissues including adrenal gland, brain, kidney, liver, lung, mammary gland, placenta, small intestine, colon, spleen, prostate and testis. The dominant HSD in prostate and mammary gland. In the prostate, higher levels in epithelial cells than in stromal cells. In the brain, expressed in medulla, spinal cord, frontotemporal lobes, thalamus, subthalamic nuclei and amygdala. Weaker expression in the hippocampus, substantia nigra and caudate.
Belongs to the aldo/keto reductase family.
研究領域
· Metabolism > Lipid metabolism > Steroid hormone biosynthesis.
· Metabolism > Lipid metabolism > Arachidonic acid metabolism.
· Metabolism > Metabolism of cofactors and vitamins > Folate biosynthesis.
· Metabolism > Global and overview maps > Metabolic pathways.
· Organismal Systems > Endocrine system > Ovarian steroidogenesis.
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.